Arrowhead Pharmaceuticals Inc (NASDAQ:ARWR) shares, rose in value on Thursday, March 27, with the stock price down by -0.93% to the previous day’s close as strong demand from buyers drove the stock to $13.80.
Actively observing the price movement in the last trading, the stock closed the session at $13.93, falling within a range of $13.68 and $14.0. The value of beta (5-year monthly) was 0.922. Referring to stock’s 52-week performance, its high was $30.41, and the low was $13.74. On the whole, ARWR has fluctuated by -28.24% over the past month.
With the market capitalization of Arrowhead Pharmaceuticals Inc currently standing at about $1.89 billion, investors are eagerly awaiting this quarter’s results, scheduled for on 2025-Feb-09.
Wall Street analysts also predicted that the company’s y-o-y revenues would reach 118.54M.
Technical indicators serve as essential tools for traders, offering insights into market sentiment and potential price movements. We see that ARWR’s technical picture suggests that short-term indicators denote the stock is a 100% Sell on average. However, medium-term indicators have put the stock in the category of 100% Sell while long-term indicators on average have been pointing out that it is a 100% Sell.
The stock’s technical analysis shows that the price of ARWR currently trading nearly -12.72% and -24.23% away from the simple moving averages for 20 and 50 days respectively. The Relative Strength Index (RSI, 14) currently indicates a reading of 31.62, while the 7-day volatility ratio is showing 5.21% which for the 30-day chart, stands at 5.80%. Furthermore, Arrowhead Pharmaceuticals Inc (ARWR)’s beta value is 0.95, and its average true range (ATR) is 0.93.
A comparison of Arrowhead Pharmaceuticals Inc (ARWR) with its peers suggests the former has fared considerably weaker in the market. ARWR showed an intraday change of -0.93% in last session, and over the past year, it shrunk by -50.52%%.
Data on historical trading for Arrowhead Pharmaceuticals Inc (NASDAQ:ARWR) indicates that the trading volumes over the past 10 days have averaged 1.61 and over the past 3 months, they’ve averaged 1.89 million. According to company’s latest data on outstanding shares, there are 125.57 million shares outstanding.
Nearly 16.87% of Arrowhead Pharmaceuticals Inc’s shares belong to company insiders and institutional investors own 70.71% of the company’s shares. The data on short interest also indicates that stock shorts accounted for 10.44 million shares as on 2025-03-14, resulting in a short ratio of 7.18. According to the data, the short interest in Arrowhead Pharmaceuticals Inc (ARWR) stood at 983.00 of shares outstanding as of 2025-03-14; the number of short shares registered in 2025-02-14 reached 9.43 million. The stock has fallen by -26.60% since the beginning of the year, thereby showing the potential of a further growth. This could raise investors’ confidence to be optimistic about the ARWR stock heading into the next quarter.
